Provided by Tiger Fintech (Singapore) Pte. Ltd.

Humacyte, Inc.

3.12
-0.0800-2.50%
Volume:1.44M
Turnover:4.45M
Market Cap:401.45M
PE:-2.30
High:3.25
Open:3.21
Low:3.02
Close:3.20
Loading ...

Company Profile

Company Name:
Humacyte, Inc.
Exchange:
NASDAQ
Establishment Date:
2004
Employees:
184
Office Location:
2525 East North Carolina Highway 54,Durham,North Carolina,United States
Zip Code:
27713
Fax:
- -
Introduction:
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Directors

Name
Position
Rajiv Shukla
Chief Executive Officer and Chairman
Brian Robertson
Director
Bruce A. Springer
Director
Kevin Xie
Director
Terrance L. Carlson
Director

Shareholders

Name
Position
Rajiv Shukla
Chief Executive Officer and Chairman
Patrick A. Sturgeon
Chief Financial Officer and Secretary